www.ecoanimalhealthgroupplc.com
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
Positive trends at ECO Animal Health
ECO Animal Health Group (LON:EAH), which makes environmentally-friendly drugs for livestock, said that trading in its current financial year has started well with “positive trends being seen” in many of its key markets.
The firm also announced that its results for the year to 31 March would be released on 25 July.
ECO, one of AIM’s longest-standing companies (it has been traded on London’s junior market since 1995 when it was known as Lawrence plc), was expected to deliver a 30 percent increase in revenues to £28.3 million for its 2011 financial year along with an adjusted pre-tax profit of £3.1 million, according to estimates made earlier this year house broker Cenkos Securities.
Accounting for almost 60 percent of ECO Animal Health’s sales, the group’s flagship product Aivlosin is a drug containing the animal antibiotic tylvalosin.
It is rapidly absorbed by animals and concentrates in target tissues to provide control of major respiratory and enteric diseases in both pigs and poultry. So far, it is licensed only for respiratory and enteric bacterial diseases in pigs and poultry, but the drug has potential to be used for other purposes.
ECO Animal Health’s range also includes Ecomectin, which is its second-biggest selling product. This endectocide is used for a broad range of parasite control, including the treatment and control of gastro-intestinal roundworms, lungworms, grubs, horn flies, sucking and biting lice as well as mites.
Results for the first half of its 2011 financial year showed that sales of Aivlosin were 55 percent ahead of H1 2010, while sales of Ecomectin were ahead by 21 percent. The boost in sales of Ecomectin was a reflection of increased demand in Japan, where the active ingredient in the product was discovered, and the well-received launch of Ecomectin in Mexico.
In March, ECO said that the staff and facilities of its Japanese subsidiary, Ecopharma, had not been affected by the earthquake and tsunami in that country.
The firm added that Ecopharma had traded satisfactorily in the second half of the 2011 financial year and its expected to deliver a full-year results in line with its budget.
